Fate Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group reports zero beneficial ownership in Fate Therapeutics Inc. following an internal realignment.
NASDAQ
Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, disclosing a 0.82% beneficial ownership stake in Fate Therapeutics, Inc. as of June 30, 2025.
NASDAQ
Goldman Sachs Group and Goldman Sachs & Co. LLC report beneficial ownership of 2.0% of Fate Therapeutics' common stock as of June 30, 2025.
NASDAQ
The Vanguard Group has disclosed a 7.64% passive ownership stake in Fate Therapeutics Inc., holding 8,766,764 shares of common stock.
NASDAQ
Schonfeld Strategic Advisors LLC has reported a significant beneficial ownership stake of 6.80% in Fate Therapeutics, Inc., holding 7,794,513 shares of common stock as of March 31, 2025.
NASDAQ
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 7.4% in Fate Therapeutics, Inc. common stock.
NASDAQ
BlackRock, Inc. has filed an Amendment No. 7 to Schedule 13G, reporting a 6.9% beneficial ownership stake in Fate Therapeutics Inc. as of March 31, 2025.